⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVS News
Novartis AG
Acute Lymphocytic Leukemia Market: Analysis and Forecast, 2025-2035
globenewswire.com
BMY
NVS
PFE
GILD
MRK
Biopharmaceutical Contract Manufacturing Market to Surpass US$ 100 Billion by 2031
globenewswire.com
NVS
PFE
CTSH
Tristan Imbert co-opted as Independent Director
globenewswire.com
SNY
NVS
Expression Therapeutics Appoints Industry Veteran Dr. David Townson as Chief Executive Officer
prnewswire.com
EXPI
PFE
NVS
Global Medical Device Contract Manufacturing Market is Predicted to Cross the USD 190 Billion Mark by 2032, Owing to the Rising Demand for Advanced Healthcare Solutions | DelveInsight
globenewswire.com
TMO
PFE
AMGN
BMY
MRK
DHR
ABBV
GOOG
MSFT
JNJ
MDT
BSX
SYK
EW
ISRG
EMR
BIOX
EXAS
QRVO
TER
ADI
TXN
ON
INTC
NVDA
AMD
HPQ
DELL
IBM
GE
FISV
ADP
PAYX
NOW
CRM
ORCL
SAP
ADSK
CDNS
SNPS
AMAT
INFY
HPE
LOGI
ATHM
BIIB
GILD
REGN
VRTX
AMRN
AZN
LLY
NVS
CRSP
EDIT
NTLA
ALNY
INCY
XRAY
COO
MASI
IRTC
MRNA
EMB
ADMA
ICUI
HOLX
LH
DGX
RDNT
EVTC
AFYA
CHKP
DDOG
SMCI
ALGN
THRY
PTC
MCHP
NXPI
QCOM
SWKS
MU
WDC
STX
Cell and Gene Therapy Market Size to Worth USD 232.22 Billion, Rising at 24% CAGR by 2035
globenewswire.com
AMGN
BIIB
NVS
PFE
REGN
NTLA
ALNY
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
globenewswire.com
NVS
MCHX
Novel Agent Ianalumab Added to Standard Therapy Extends Time to Treatment Failure in Patients with Previously Treated Immune Thrombocytopenia
prnewswire.com
NVS
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
globenewswire.com
NVS
Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases
globenewswire.com
NVS